IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,866 shares of the company’s stock after selling 6,036 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in IDEXX Laboratories were worth $14,002,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Public Sector Pension Investment Board lifted its position in IDEXX Laboratories by 67.6% during the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock worth $1,500,000 after buying an additional 1,241 shares in the last quarter. Marshall Wace LLP increased its stake in shares of IDEXX Laboratories by 2.5% in the 2nd quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock worth $9,988,000 after acquiring an additional 500 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth $933,000. Daymark Wealth Partners LLC boosted its position in shares of IDEXX Laboratories by 37.1% during the 2nd quarter. Daymark Wealth Partners LLC now owns 621 shares of the company’s stock valued at $303,000 after acquiring an additional 168 shares during the last quarter. Finally, MBB Public Markets I LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at about $2,931,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IDXX. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $435.33 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a market capitalization of $35.65 billion, a P/E ratio of 41.98, a P/E/G ratio of 3.63 and a beta of 1.36. The company’s fifty day moving average price is $423.74 and its 200 day moving average price is $456.35.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.53 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.